Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
997 people get PATH articles and Market Currents by email alert.
Get email alerts on PATH »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
Nupathe's Zelrix Going Down A Path With Multiple HeadwindsScriptVolume • Fri, Dec 9, 2011 -
-
-
NuPathe Trades at Discount to IPO Price with Near-Term FDA FilingMike Havrilla • Tue, Sep 21, 2010
-
Biotech IPO: NuPatheSA Editor Mohit Manghnani • Fri, Aug 6, 2010
-
-
-
-
-
-
5 Biotechs With January FDA Decision Date CatalystsDavid Zanoni • Mon, Dec 17, 2012
-
-
-
-
-
-
-
-
-
-
-
-
-
-
John Burbank And Insiders Are Bullish On These 18 StocksInsider Monkey • Mon, Oct 24, 2011
-
NuPathe's CEO Discusses Q2 2013 Results - Earnings Call TranscriptMon, Nov 12, 2012
-
NuPathe Management Discusses Q2 2012 Results - Earnings Call TranscriptTue, Aug 14, 2012 • 2 Comments
-
Marketwire (May 28, 2013)
-
Marketwire (May 14, 2013)
-
Marketwire (May 13, 2013)
-
Marketwire (May 7, 2013)
-
Marketwire (Apr 25, 2013)
-
Marketwire (Mar 26, 2013)
-
Marketwire (Feb 6, 2013)
-
Marketwire (Jan 17, 2013)
-
Marketwire (Jan 2, 2013)
-
Marketwire (Nov 27, 2012)
-
Marketwire (Nov 12, 2012)
-
Marketwire (Nov 7, 2012)
-
Marketwire (Nov 5, 2012)
-
Marketwire (Oct 23, 2012)
-
Marketwire (Oct 12, 2012)
-
Marketwire (Oct 8, 2012)
-
at MarketWatch.com (Sep 26, 2012)
-
Marketwire (Sep 25, 2012)
-
Marketwire (Aug 14, 2012)
PATH vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. Following are the key information about our existing product candidates. We hold... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, June 6, 1:18 PM Shares of NuPathe (PATH -1%) are lower again today, extending a week-long decline on no specific news. The stock took an accelerated turn to the downside in early trading, cratering nearly 14% on what looks like capitulation selling before recovering most of the losses. Comment! [Healthcare, On the Move]
-
Friday, May 17, 5:42 PM
After-hours top gainers, as of 5:15 p.m.: GAIA +7.6%. ADK +6.4%. PATH +5.3%. GST +4.2%. DQ +3.3%.
After-hours top losers: DATA -5.1%. QEP -3.8%. CPRT -3.8%. RPAI -3.6%. EA -2.3%. Comment! [On the Move] - Tuesday, May 14, 2:15 PM NuPathe (PATH -2.4%) slides after posting a Q1 loss of $0.21 per share earlier today, versus the consensus loss of $0.19 per share. The company did not record revenues for the quarter, as expected. The miss can be attributed to dilution stemming from the automatic conversion of its Series A Preferred Stock, which was triggered in February, resulting in the conversion of 100% of the outstanding into common stock, as well as the termination of a "full ratchet" anti-dilution feature on warrants issued in connection with the preferred stock in October 2012. 3 Comments [Healthcare, Earnings, On the Move]
- Tuesday, March 26, 11:47 AM NuPathe (PATH -6.6%) slips after its Q4 EPS loss came in much greater than expected. Net loss, including items, was $19.1M, wider than the loss reported in the prior year period. Despite the miss, CEO Armando Anido was upbeat in his comments, saying the company remains focused on securing commercial partners and preparing for the commercial launch of Zecuity, the first and only prescription migraine patch, which is expected in Q4. Comment! [Healthcare, On the Move, Earnings]
-
Tuesday, March 26, 9:15 AM
Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move] - Tuesday, March 26, 7:37 AM NuPathe Inc (PATH): Q4 EPS of -$1.15. Shares +3.8% premarket. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
-
Friday, January 18, 9:10 AM
Premarket gainers: PATH +16%. LIFE +12%. NEWL +8%. RIMM +8%. MS +7%. SNE +7%. GERN +5%.
Losers: FNSR -10%. TSRX -9%. WIT -8%. COF -7%. INTC -6%.
2 Comments [On the Move] - Thursday, January 17, 7:56 PM The FDA approves NuPathe's (PATH) Zecuity for the acute treatment of migraine with or without aura in adults. The drug is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin. Shares surge +18% after resuming trade following an earlier halt. 3 Comments [Healthcare, On the Move]
- Thursday, January 17, 6:02 PM Shares of NuPathe (PATH) have been halted with news pending. The company has a PDUFA date today for its Zecuity migraine patch. Shares -1% AH. Comment! [Healthcare]
-
Thursday, January 17, 5:40 PM
After-hours top gainers, as of 5:15 p.m.: AM +9%. ARAY +4%. SOXS +3%. EGLE +3%. ONXX +2%.
After-hours top losers: COF -8%. TSRX -6%. PATH -5%. INTC -4%. MAKO -3%. Comment! [On the Move] -
Thursday, January 17, 9:10 AM
Premarket gainers: NEWL +64%. KSWS +48%. PATH +11%. CBS +9%. ROYL +8%. NUS +6%.
Losers: CLSN -10%. AVEO -5%. Comment! [On the Move] - Wednesday, January 2, 2:00 PM NuPathe (PATH +2.5%) says the U.S. Patent & Trademark Office has accepted its patent application for iontophoretic patches, a migraine treatment containing the company's proprietary hydrogel polyamine formulation. The company expects the patent to be issued within the next few months, and should provide additional patent protection for its existing migraine treatment Zecuity. Comment! [Healthcare, On the Move]
-
Friday, December 21, 2012, 5:38 PM
After-hours top gainers, as of 5:15 p.m.: TFSL +6%. PACT +3%. PBRA +3%. DANG +3%. OIBRC +2%.
After-hours top losers: ALXA -13.13%. PATH -7%. SVU -4%. TXT -4%. NSU -4%. 1 Comment [On the Move] - Monday, November 12, 2012, 3:38 PM Shares of NuPathe (PATH -2%) are lower today after reporting a Q3 loss of $0.42 per share, below the Street consensus of a $0.36 per share loss. The company didn't report revenues for the quarter, which was expected. On a per share basis, earnings sank 29% Y/Y as the company's bottom line was negatively impacted by higher costs associated with separation expenses related to the resignation of its former CEO as well as the elimination of 15 full-time positions. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, October 9, 2012, 9:05 AM NuPathe (PATH) intends to reduce its workforce by half in order to cut expenses and focus on receiving approval for its NP101 migraine patch. The company, which has almost 40 employees, will also lower marketing costs, and postpone the application for its NP202 drug for schizophrenia and bipolar disorder until it finds a partner. NuPathe is trying to raise $28M in financing. (PR) Comment! [Healthcare]
-
Wednesday, September 26, 2012, 12:45 PM
Midday top 10 gainers: LPHI +112%. CTC +18%. AM +17%. STSI +15%. KCG +11%. WCBO +11%. CAMP +10%. DIAL +10%. SCMP +10%. SVN +8%.
Top 10 Losers: PATH -27%. BTH -19%. OMN -14%. RMKR -13%. CPRX -13%. TISA -12%. GEVO -12%. MITK -12%. OINK -12%. TSTC -11%. Comment! [On the Move]
-
- View all 0 replies
-
- View all 8 replies
-
-
-
pagreen1966
$PATH flat yesterday because still no announcement of partner. Expect news within the month. - View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 30 replies
-
-
StockMatusow: so no, I don't believe u do well in the market at all, no one who chides success can possibly be a real market winner with any real money
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/ObIXDN New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, /4HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN - View all 1 replies
-
LATEST REPLIES
-
pagreen1966
$PATH flat yesterday because still no announcement of partner. Expect news within the month. - View all 1 replies
-
-
- View all 8 replies
-
-
-
- View all 30 replies
-
-
StockMatusow: so no, I don't believe u do well in the market at all, no one who chides success can possibly be a real market winner with any real money
-
freefdawatchlist
http://bit.ly/ObIXDN New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, /4HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN - View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Scott Matusow
$IBIO and $PATH because both offer the biggest multi bag potential if things work out for them $PSDV as well - View all 1 replies
-
Winning Will: Scott, good news out for HZNP .you still holding shares? I bought in at 3.70 sold a small portion at 4.25 before it fell. Thnks 4 this one!
-
Scott Matusow
PATH went down to my short term target of $4. like this one a lot for a double this year. grossly undervalued. was recently as high as $5.10 - View all 18 replies
-
StockMatusow: that was the initial public offering, they need another one, as the can use the money and the stock needs a bit more liquidity
-
Rodney_Braswell: I will take that. I am not going to do anything with it. I am just going to let it sit there until...
-
- View all 5 replies
-
NightRaider: That was not expected. Where no confidence I keep zero trail stops
-
Winning Will: how do you think we will fair up until we get some updates on the pipeline
-
- View all 10 replies
-
ArincTheAdanian: You are Awesome. Thanks indeed... Agree w/ all of the medical rationale mentioned within your blog! -
ArincTheAdanian: You are Awesome. Thanks indeed... Agree w/ all of the medical rationale mentioned within your blog!
We are a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. Following are the key information about our existing product candidates. We hold worldwide commercialization rights to all of our product candidates: Zelrix , NP201 , NP202.